[Articles] Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

The randomised phase 3 PANKU-Breast01 trial showed that izalontamab brengitecan significantly improved progression-free survival over chemotherapy in Chinese patients with HR+/HER2– breast cancer previously treated with endocrine therapy, CDK4/6 inhibitors, and one or two lines of chemotherapy including taxanes. Overall survival data were immature and a survival benefit has not been established. The original article says the results may offer a new treatment option for this Chinese population and recommends further evaluation in global populations and earlier treatment lines of HER2-negative breast cancer.